OptiNose, Inc. (OPTN)
After hours:
| Previous Close | 0.9677 |
| Open | 0.9507 |
| Bid | 0.9177 x 100 |
| Ask | 0.9331 x 100 |
| Day's Range | 0.8907 - 0.9630 |
| 52 Week Range | 0.8550 - 2.1000 |
| Volume | |
| Avg. Volume | 618,543 |
| Market Cap | 104.237M |
| Beta (5Y Monthly) | -0.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3200 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.75 |
Simply Wall St.OptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years ago
OptiNose, Inc. ( NASDAQ:OPTN ) shareholders should be happy to see the share price up 13% in the last quarter. But will...
GlobeNewswireOptinose to Present at the Needham Virtual Healthcare Conference
YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024 at 2:15 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will
- GlobeNewswire
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical trial program also showed reduction in sinus inflammation and in acute exacerbations, which frequently result in use of antibiotics XHANCE uses the proprietary Exhalation Delivery System to enable deposition of a proven steroid in target areas of inflammation deep in the nose not typically reached by s
